Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Berton-Rigaud, Dominique
96  Ergebnisse:
Personensuche X
?
1

Spatial profiling of ovarian carcinoma and tumor microenvir..:

Yaniz-Galende, Elisa ; Zeng, Qinghe ; Grau-Bejar, Juan Francisco...
Clinical Cancer Research.  , 2024
Link: https://doi.org/10.1158/..
 
?
2

Dissecting the Origin of Heterogeneity in Uterine and Ovari..:

Sertier, Anne-Sophie ; Ferrari, Anthony ; Pommier, Roxane M....
Cancer Research Communications.  3 (2023)  5 - p. 830-841 , 2023
Link: https://doi.org/10.1158/..
 
?
3

Surgical Implications of Advanced Low-Grade Serous Ovarian ..:

Bonsang-Kitzis, Hélène ; Panchbhaya, Nabilah ; Bats, Anne-Sophie...
Cancers.  14 (2022)  9 - p. 2345 , 2022
Link: https://doi.org/10.3390/..
 
?
4

Chronic fatigue, quality of life and long-term side-effects..:

Gernier, François ; Ahmed-Lecheheb, Djihane ; Pautier, Patricia...
BMC Cancer.  21 (2021)  1 - p. , 2021
Link: https://doi.org/10.1186/..
 
?
5

Comparative analysis of predictive values of the kinetics o..:

Robelin, Patrick ; Tod, Michel ; Colomban, Olivier...
Gynecologic Oncology.  159 (2020)  1 - p. 256-263 , 2020
Link: https://doi.org/10.1016/..
 
?
6

Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carbo..:

Romeo, Clémence ; Joly, Florence ; Ray-Coquard, Isabelle...
Gynecologic Oncology.  152 (2019)  1 - p. 68-75 , 2019
Link: https://doi.org/10.1016/..
 
?
7

Pembrolizumab in patients with programmed death ligand 1–po..:

Varga, Andrea ; Piha-Paul, Sarina ; Ott, Patrick A....
Gynecologic Oncology.  152 (2019)  2 - p. 243-250 , 2019
Link: https://doi.org/10.1016/..
 
?
8

Measuring what matters MOST: validation of the Measure of O..:

King, Madeleine T. ; Stockler, Martin R. ; O'Connell, Rachel L....
Quality of Life Research.  27 (2018)  1 - p. 59-74 , 2018
Link: https://www.jstor.org/st..
 
?
9

Phase I study of onapristone, a type I antiprogestin, in fe..:

Cottu, Paul H. ; Bonneterre, Jacques ; Varga, Andrea...
PLOS ONE.  13 (2018)  10 - p. e0204973 , 2018
Link: https://doi.org/10.1371/..
 
?
10

A phase 1 study of lirilumab (antibody against killer immun..:

Vey, Norbert ; Karlin, Lionel ; Sadot-Lebouvier, Sophie...
Oncotarget.  9 (2018)  25 - p. 17675-17688 , 2018
Link: https://doi.org/10.18632..
 
?
11

Validation of the modified Glasgow Prognostic Score (mGPS) ..:

Roncolato, Felicia T. ; Berton-Rigaud, Dominique ; O'Connell, Rachel...
Gynecologic Oncology.  148 (2018)  1 - p. 36-41 , 2018
Link: https://doi.org/10.1016/..
 
?
12

Reducing Uncertainty: Predictors of Stopping Chemotherapy E..:

Roncolato, Felicia T. ; Joly, Florence ; O'Connell, Rachel...
The Oncologist.  22 (2017)  9 - p. 1117-1124 , 2017
Link: https://doi.org/10.1634/..
 
?
13

Measuring what matters MOST: validation of the Measure of O..:

for the GCIG Symptom Benefit group ; King, Madeleine T. ; Stockler, Martin R....
Quality of Life Research.  27 (2017)  1 - p. 59-74 , 2017
Link: https://doi.org/10.1007/..
 
?
14

Communicating BRCA research results to patients enrolled in..:

Pulford, David J. ; Harter, Philipp ; Floquet, Anne...
BMC Medical Ethics.  17 (2016)  1 - p. , 2016
Link: https://doi.org/10.1186/..
 
?
15

BRCA1/2 mutations associated with progression-free survival..:

Harter, Philipp ; Johnson, Toby ; Berton-Rigaud, Dominique...
Gynecologic Oncology.  140 (2016)  3 - p. 443-449 , 2016
Link: https://doi.org/10.1016/..
 
1-15